40 episodes

The power of data is remaking everything in healthcare—not just the way doctors diagnose patients, but the way pharma companies develop drugs and the way hospitals and insurers control costs and create value. Here at MoneyBall Medicine, host Harry Glorikian talks with the executives, entrepreneurs, physicians, and scientists who are pushing that high-tech revolution forward. Harry's 2017 book "MoneyBall Medicine" offered an inside look at the ways genomics, machine learning, and other trends are improving healthcare delivery and efficiency. And now he brings you intimate conversations with industry pioneers—like Mount Sinai's Joel Dudley, N-of-One's Jennifer Carter, Semeion's Massimo Buscema, Genetic Alliance's Sharon Terry, and many more—who share their hard-won experience in the surprising, exciting, untamed world of data-driven healthcare.

MoneyBall Medicine Harry Glorikian

    • Medicine
    • 5.0, 13 Ratings

The power of data is remaking everything in healthcare—not just the way doctors diagnose patients, but the way pharma companies develop drugs and the way hospitals and insurers control costs and create value. Here at MoneyBall Medicine, host Harry Glorikian talks with the executives, entrepreneurs, physicians, and scientists who are pushing that high-tech revolution forward. Harry's 2017 book "MoneyBall Medicine" offered an inside look at the ways genomics, machine learning, and other trends are improving healthcare delivery and efficiency. And now he brings you intimate conversations with industry pioneers—like Mount Sinai's Joel Dudley, N-of-One's Jennifer Carter, Semeion's Massimo Buscema, Genetic Alliance's Sharon Terry, and many more—who share their hard-won experience in the surprising, exciting, untamed world of data-driven healthcare.

    Covid-19 Tracing Inside Companies, with SaferMe's Clint Van Marrewijk

    Covid-19 Tracing Inside Companies, with SaferMe's Clint Van Marrewijk

    Harry's guest this week is the founder and CEO of a New Zealand firm, SaferMe, that had developed proximity-based smartphone apps for worker safety. When the coronavirus came along, their apps turned out to be a great way to help companies build their own "contact tables" to identify, test, and isolate SARS-CoV-2 carriers.

    • 29 min
    Ulo Palm on P-Values: What They Are and Why They're Past Their Prime

    Ulo Palm on P-Values: What They Are and Why They're Past Their Prime

    This week Harry quizzes Ulo Palm, the senior vice president of digital sciences at Allergan, about the long and problematic reign of the p-value in statistical analysis, and why it may be time for the biopharma industry to look to more nuanced measures of whether a drug trial succeeded.

    • 42 min
    How Data Is Critical to Engineering Antibodies to Block COVID-19

    How Data Is Critical to Engineering Antibodies to Block COVID-19

    Distributed Bio aims to use its computational antibody engineering platform to identify antibodies that protect against SARS and optimize them to block the SARS-CoV2 coronavirus. This week Harry gets an progress update from three key Distributed Bio scientists.

    • 34 min
    Jacob Glanville Confronts Coronavirus Through Immuno-engineering

    Jacob Glanville Confronts Coronavirus Through Immuno-engineering

    Harry's guest for this unusually frank and urgent episode is Jacob Glanville, the founding partner, CEO, and president of Distributed Bio. The company is using its skills in computational antibody analysis and optimization to help the drug industry develop new vaccines and antibody-based treatments for a range of diseases, potentially including the coronavirus that causes COVID-19.

    • 54 min
    Ramy Farid on the Power of Computation in Drug Discovery

    Ramy Farid on the Power of Computation in Drug Discovery

    Harry interviews Ramy Farid, president and CEO of Schrödinger Pharmaceuticals, about the company's success using chemical simulation software to help drug makers zero in on promising drug candidates—and about its recent IPO, which brought in more than twice as much cash as the company expected.

    • 28 min
    Illumina's Phil Febbo on Sequencing, Coronavirus and Viral Outbreaks

    Illumina's Phil Febbo on Sequencing, Coronavirus and Viral Outbreaks

    As the Wuhan coronavirus outbreak spreads in Asia, Harry speaks with Phil Febbo, the chief medical officer of Illumina, one of the world's largest makers of equipment for high-throughput DNA sequencing. Febbo highlights sequencing's emerging contribution to the understanding and treatment of infectious disease.

    • 28 min

Customer Reviews

5.0 out of 5
13 Ratings

13 Ratings

menziggy ,

Love it as a layman!

While I’m not in the life sciences industry, I find this series really interesting! I’m learning so much and the topics are pretty focused to a single area, so even a layperson like me gets smarter.

WorldWideWade ,

Smart, informative, wide-ranging

I’ve been listening since the beginning. You won’t find a better show about how AI and other digital technologies are transforming the healthcare industry.

KD-Denver ,

Great podcast!

Great topics from 50,000 ft level of health care to specifics of how to improve systems, diagnostics and treatments

Top Podcasts In Medicine

Listeners Also Subscribed To